<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: others statements", fill: "#fffaf0"},
{source: "2: others statements", target: "2: expectation", fill: "#fffaf0"},
{source: "2: expectation", target: "2: profitability", fill: "#fffaf0"},
{source: "2: profitability", target: "2: clinical studies", fill: "#fffaf0"},
{source: "2: clinical studies", target: "2: regulatory filings", fill: "#fffaf0"},
{source: "2: regulatory filings", target: "2: achievement", fill: "#fffaf0"},
{source: "2: achievement", target: "2: regulatory approvals", fill: "#fffaf0"},
{source: "2: regulatory approvals", target: "2: find alternate sources", fill: "#fffaf0"},
{source: "2: find alternate sources", target: "2: manufacturing", fill: "#fffaf0"},
{source: "2: manufacturing", target: "2: activities", fill: "#fffaf0"},
{source: "2: activities", target: "2: competitors", fill: "#fffaf0"},
{source: "2: competitors", target: "2: pay dividends on common stock", fill: "#fffaf0"},
{source: "2: pay dividends on common stock", target: "2: common stock", fill: "#fffaf0"},
{source: "2: common stock", target: "2: foreseeable future", fill: "#fffaf0"},
{source: "2: foreseeable future", target: "2: Remodulin ", fill: "#fffaf0"},
{source: "2: Remodulin ", target: "2: patient", fill: "#fffaf0"},
{source: "2: patient", target: "2: consumption", fill: "#fffaf0"},
{source: "2: consumption", target: "2: of Remodulin ", fill: "#fffaf0"},
{source: "2: of Remodulin ", target: "2: Remodulin ", fill: "#fffaf0"},
{source: "2: Remodulin ", target: "2: on future revenues", fill: "#fffaf0"},
{source: "2: on future revenues", target: "2: intravenous", fill: "#fffaf0"},
{source: "2: intravenous", target: "2: Remodulin ", fill: "#fffaf0"},
{source: "2: Remodulin ", target: "2: thirdparty", fill: "#fffaf0"},
{source: "2: thirdparty", target: "2: Medicare ", fill: "#fffaf0"},
{source: "2: Medicare ", target: "2: of the Remodulin Phase IV ", fill: "#fffaf0"},
{source: "2: of the Remodulin Phase IV ", target: "2: Remodulin Phase IV ", fill: "#fffaf0"},
{source: "2: Remodulin Phase IV ", target: "2: clinical trial", fill: "#fffaf0"},
{source: "2: clinical trial", target: "2: acceptance by", fill: "#fffaf0"},
{source: "2: acceptance by", target: "2: interim study", fill: "#fffaf0"},
{source: "2: interim study", target: "2: warning letters", fill: "#fffaf0"},
{source: "2: warning letters", target: "2: patient acceptance", fill: "#fffaf0"},
{source: "2: patient acceptance", target: "2: products as safe", fill: "#fffaf0"},
{source: "2: products as safe", target: "2: effective", fill: "#fffaf0"},
{source: "2: effective", target: "2: development", fill: "#fffaf0"},
{source: "2: development", target: "2: products covered by licenses", fill: "#fffaf0"},
{source: "2: products covered by licenses", target: "2: assignments", fill: "#fffaf0"},
{source: "2: assignments", target: "2: intellectual property protections", fill: "#fffaf0"},
{source: "2: intellectual property protections", target: "2: litigation", fill: "#fffaf0"},
{source: "2: litigation", target: "2: become involved", fill: "#fffaf0"},
{source: "2: become involved", target: "2: third parties", fill: "#fffaf0"},
{source: "2: third parties", target: "2: market distribute", fill: "#fffaf0"},
{source: "2: market distribute", target: "2: composition", fill: "#fffaf0"},
{source: "2: composition", target: "2: management team", fill: "#fffaf0"},
{source: "2: management team", target: "2: insurance coverage", fill: "#fffaf0"},
{source: "2: insurance coverage", target: "2: operations from future revenues", fill: "#fffaf0"},
{source: "2: operations from future revenues", target: "2: continued profits", fill: "#fffaf0"},
{source: "2: continued profits", target: "2: discontinuance", fill: "#fffaf0"},
{source: "2: discontinuance", target: "2: HeartBar ", fill: "#fffaf0"},
{source: "2: HeartBar ", target: "2: expectations concerning milestone", fill: "#fffaf0"},
{source: "2: expectations concerning milestone", target: "2: royalty payments", fill: "#fffaf0"},
{source: "2: royalty payments", target: "2: expectations concerning payments", fill: "#fffaf0"},
{source: "2: expectations concerning payments", target: "2: contractual obligations", fill: "#fffaf0"},
{source: "2: contractual obligations", target: "2: future years", fill: "#fffaf0"},
{source: "2: future years", target: "2: loss carryforwards", fill: "#fffaf0"},
{source: "2: loss carryforwards", target: "2: carryforwards", fill: "#fffaf0"},
{source: "2: carryforwards", target: "2: Internal Revenue Code ", fill: "#fffaf0"},
{source: "2: Internal Revenue Code ", target: "2: income tax expenses", fill: "#fffaf0"},
{source: "2: income tax expenses", target: "2: future periods", fill: "#fffaf0"},
{source: "2: future periods", target: "2: completion", fill: "#fffaf0"},
{source: "2: completion", target: "2: inprocess research", fill: "#fffaf0"},
{source: "2: inprocess research", target: "2: impact on", fill: "#fffaf0"},
{source: "2: impact on", target: "2: enrollment", fill: "#fffaf0"},
{source: "2: enrollment", target: "2: clinical trials", fill: "#fffaf0"},
{source: "2: clinical trials", target: "2: expectation outcome", fill: "#fffaf0"},
{source: "2: expectation outcome", target: "2: continuing regulatory", fill: "#fffaf0"},
{source: "2: continuing regulatory", target: "2: applications", fill: "#fffaf0"},
{source: "2: applications", target: "2: subcutaneous", fill: "#fffaf0"},
{source: "2: subcutaneous", target: "2: approve subcutaneous", fill: "#fffaf0"},
{source: "2: approve subcutaneous", target: "2: Remodulin ", fill: "#fffaf0"},
{source: "2: Remodulin ", target: "2: of Remodulin ", fill: "#fffaf0"},
{source: "2: of Remodulin ", target: "2: fund operations", fill: "#fffaf0"},
{source: "2: fund operations", target: "2: laboratory", fill: "#fffaf0"},
{source: "2: laboratory", target: "2: production facility", fill: "#fffaf0"},
{source: "2: production facility", target: "2: Silver Spring Maryland ", fill: "#fffaf0"},
{source: "2: Silver Spring Maryland ", target: "2: minimum residual value guarantee", fill: "#fffaf0"},
{source: "2: minimum residual value guarantee", target: "2: upon termination", fill: "#fffaf0"},
{source: "2: upon termination", target: "2: of the Wachovia ", fill: "#fffaf0"},
{source: "2: of the Wachovia ", target: "2: agreements", fill: "#fffaf0"},
{source: "2: agreements", target: "2: potential impacts", fill: "#fffaf0"},
{source: "2: potential impacts", target: "2: new accounting standards", fill: "#fffaf0"},
{source: "2: new accounting standards", target: "2: common stock at", fill: "#fffaf0"},
{source: "2: common stock at", target: "2: terms under", fill: "#fffaf0"},
{source: "2: terms under", target: "2: registration statement filed with", fill: "#fffaf0"},
{source: "2: registration statement filed with", target: "2: SEC in February ", fill: "#fffaf0"},
{source: "2: SEC in February ", target: "2: certain marketable investments until", fill: "#fffaf0"},
{source: "2: certain marketable investments until", target: "2: statements preceded by followed by", fill: "#fffaf0"},
{source: "2: statements preceded by followed by", target: "2: should may", fill: "#fffaf0"},
{source: "2: should may", target: "2: expressions", fill: "#fffaf0"},
{source: "2: expressions", target: "2: statements contained", fill: "#fffaf0"},
{source: "2: statements contained", target: "2: incorporated by reference", fill: "#fffaf0"},
{source: "2: incorporated by reference", target: "2: Annual Report ", fill: "#fffaf0"},
{source: "2: Annual Report ", target: "2: historical facts", fill: "#fffaf0"},
{source: "2: others statements", target: "16: could affect consolidated revenues", fill: "#ae0c00"},
{source: "16: could affect consolidated revenues", target: "16: profitability", fill: "#ae0c00"},
{source: "16: profitability", target: "16: of Remodulin ", fill: "#ae0c00"},
{source: "16: of Remodulin ", target: "16: Remodulin ", fill: "#ae0c00"},
{source: "16: Remodulin ", target: "16: distributors", fill: "#ae0c00"},
{source: "16: distributors", target: "16: Levels of Remodulin ", fill: "#ae0c00"},
{source: "16: Levels of Remodulin ", target: "16: levels from quarter", fill: "#ae0c00"},
{source: "16: levels from quarter", target: "16: patient", fill: "#ae0c00"},
{source: "16: patient", target: "16: prescribers", fill: "#ae0c00"},
{source: "16: prescribers", target: "16: development", fill: "#ae0c00"},
{source: "16: development", target: "16: administrative", fill: "#ae0c00"},
{source: "16: administrative", target: "16: licensors", fill: "#ae0c00"},
{source: "16: licensors", target: "16: Retention ", fill: "#ae0c00"},
{source: "16: Retention ", target: "16: infusion site pain", fill: "#ae0c00"},
{source: "16: infusion site pain", target: "16: reaction from subcutaneous use", fill: "#ae0c00"},
{source: "16: reaction from subcutaneous use", target: "16: current pricing", fill: "#ae0c00"},
{source: "16: current pricing", target: "16: Changes ", fill: "#ae0c00"},
{source: "16: Changes ", target: "16: therapies approved", fill: "#ae0c00"},
{source: "16: therapies approved", target: "16: of other PAH ", fill: "#ae0c00"},
{source: "16: of other PAH ", target: "16: possible generic formulations", fill: "#ae0c00"},
{source: "16: possible generic formulations", target: "16: approved therapies such as", fill: "#ae0c00"},
{source: "16: approved therapies such as", target: "16: Willingness ", fill: "#ae0c00"},
{source: "16: Willingness ", target: "16: Medicare and Medicaid ", fill: "#ae0c00"},
{source: "16: Medicare and Medicaid ", target: "16: at current pricing levels", fill: "#ae0c00"},
{source: "16: at current pricing levels", target: "16: legislation", fill: "#ae0c00"},
{source: "16: legislation", target: "16: regulations", fill: "#ae0c00"},
{source: "16: regulations", target: "16: Remodulin Phase IV ", fill: "#ae0c00"},
{source: "16: Remodulin Phase IV ", target: "16: regulatory", fill: "#ae0c00"},
{source: "16: regulatory", target: "16: United States ", fill: "#ae0c00"},
{source: "16: United States ", target: "16: Additional ", fill: "#ae0c00"},
{source: "16: Additional ", target: "16: regulatory approvals", fill: "#ae0c00"},
{source: "16: regulatory approvals", target: "16: approved competitive products such as", fill: "#ae0c00"},
{source: "16: approved competitive products such as", target: "16: competitive", fill: "#ae0c00"},
{source: "16: competitive", target: "16: to the Medicare and Medicaid ", fill: "#ae0c00"},
{source: "16: to the Medicare and Medicaid ", target: "16: postmarketing study", fill: "#ae0c00"},
{source: "16: postmarketing study", target: "16: investigational", fill: "#ae0c00"},
{source: "16: investigational", target: "16: ambrisentan", fill: "#ae0c00"},
{source: "16: ambrisentan", target: "16: investigational competitive products", fill: "#ae0c00"},
{source: "16: investigational competitive products", target: "16: Continued ", fill: "#ae0c00"},
{source: "16: Continued ", target: "16: performance by current", fill: "#ae0c00"},
{source: "16: performance by current", target: "16: distributors under", fill: "#ae0c00"},
{source: "16: distributors under", target: "16: agreements", fill: "#ae0c00"},
{source: "16: agreements", target: "16: development efforts", fill: "#ae0c00"},
{source: "16: development efforts", target: "16: additional", fill: "#ae0c00"},
{source: "16: additional", target: "16: royalty payments under license", fill: "#ae0c00"},
{source: "16: royalty payments under license", target: "16: regulatory reviews", fill: "#ae0c00"},
{source: "16: regulatory reviews", target: "16: technological", fill: "#ae0c00"},
{source: "16: technological", target: "16: establish defend", fill: "#ae0c00"},
{source: "16: establish defend", target: "16: enforce intellectual property", fill: "#ae0c00"},
{source: "16: enforce intellectual property", target: "16: Development ", fill: "#ae0c00"},
{source: "16: Development ", target: "16: manufacturing", fill: "#ae0c00"},
{source: "16: manufacturing", target: "16: establishment", fill: "#ae0c00"},
{source: "16: establishment", target: "16: continuation", fill: "#ae0c00"},
{source: "16: continuation", target: "16: termination", fill: "#ae0c00"},
{source: "16: termination", target: "16: or the Establishment ", fill: "#ae0c00"},
{source: "16: or the Establishment ", target: "16: trial arrangements", fill: "#ae0c00"},
{source: "16: trial arrangements", target: "16: thirdparty sales", fill: "#ae0c00"},
{source: "16: thirdparty sales", target: "16: marketing arrangements", fill: "#ae0c00"},
{source: "16: marketing arrangements", target: "16: or the Impact ", fill: "#ae0c00"},
{source: "16: or the Impact ", target: "16: restrictions", fill: "#ae0c00"},
{source: "16: restrictions", target: "16: activities", fill: "#ae0c00"},
{source: "16: activities", target: "16: Recovery ", fill: "#ae0c00"},
{source: "16: Recovery ", target: "16: investments", fill: "#ae0c00"},
{source: "16: investments", target: "16: affiliates", fill: "#ae0c00"},
{source: "16: affiliates", target: "16: Collection ", fill: "#ae0c00"},
{source: "16: Collection ", target: "16: accounts", fill: "#ae0c00"},
{source: "16: accounts", target: "16: realization", fill: "#ae0c00"},
{source: "16: realization", target: "16: inventories", fill: "#ae0c00"},
{source: "16: inventories", target: "16: associated with acquisitions", fill: "#ae0c00"},
{source: "16: associated with acquisitions", target: "16: acquisitions", fill: "#ae0c00"},
{source: "16: acquisitions", target: "16: businesses", fill: "#ae0c00"},
{source: "16: businesses", target: "16: Unforeseen ", fill: "#ae0c00"},
{source: "16: Unforeseen ", target: "16: telemedicine", fill: "#ae0c00"},
{source: "16: telemedicine", target: "16: arginine products", fill: "#ae0c00"},
{source: "16: arginine products", target: "16: expenses incurred", fill: "#ae0c00"},
{source: "16: expenses incurred", target: "16: future periods", fill: "#ae0c00"},
{source: "16: future periods", target: "16: Completion ", fill: "#ae0c00"},
{source: "16: could affect consolidated revenues", target: "28: by intravenous", fill: "#fad6a5"},
{source: "28: by intravenous", target: "28: effective treatment by most", fill: "#fad6a5"},
{source: "28: effective treatment by most", target: "28: December ", fill: "#fad6a5"},
{source: "28: December ", target: "28: United States ", fill: "#fad6a5"},
{source: "28: United States ", target: "28: September ", fill: "#fad6a5"},
{source: "28: by intravenous", target: "98: Phase IV ", fill: "#002366"},
{source: "98: Phase IV ", target: "98: clinical trial", fill: "#002366"},
{source: "98: clinical trial", target: "98: been fully enrolled by", fill: "#002366"},
{source: "98: Phase IV ", target: "START_HERE", fill: "#002366"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>IT Consulting and Other Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Hypermarkets and Super Centers</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treprostinil">Treprostinil</a></td>
      <td>Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of  pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Therapeutics">United Therapeutics</a></td>
      <td>United Therapeutics Corporation is an American publicly traded biotechnology company listed on the NASDAQ under the symbol UTHR. It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville Florida; La Jolla, California; and Manchester, New Hampshire.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pulmonary_hypertension">Pulmonary hypertension</a></td>
      <td>Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure in the arteries of the lungs. Symptoms include shortness of breath, fainting, tiredness, chest pain, swelling of the legs, and a fast heartbeat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prostacyclin">Prostacyclin</a></td>
      <td>Prostacyclin (also called prostaglandin I2 or PGI2) is a prostaglandin member of the eicosanoid family of lipid molecules. It inhibits platelet activation and is also an effective vasodilator.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_altruism">Effective altruism</a></td>
      <td>Effective altruism (EA) is a philosophical and social movement that advocates "using evidence and reason to figure out how to benefit others as much as possible, and taking action on that basis". People who pursue the goals of effective altruism are labeled effective altruists.Common practices of effective altruists include significant charitable donation, and choosing careers based on the amount of good that the career achieves, which may include the strategy of earning to give.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_temperature">Effective temperature</a></td>
      <td>The effective temperature of a body such as a star or planet is the temperature of a black body that would emit the same total amount of electromagnetic radiation.  Effective temperature is often used as an estimate of a body's surface temperature when the body's emissivity curve (as a function of wavelength) is not known.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_method">Effective method</a></td>
      <td>In logic, mathematics and computer science, especially metalogic and computability theory, an effective method or effective procedure is a procedure for solving a problem by any intuitively 'effective' means from a specific class. An effective method is sometimes also called a mechanical method or procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_radiated_power">Effective radiated power</a></td>
      <td>Effective radiated power (ERP), synonymous with equivalent radiated power,  is an IEEE standardized definition of directional radio frequency (RF) power, such as that emitted by a radio transmitter.  It is the total power in watts that would have to be radiated by a half-wave dipole antenna to give the same radiation intensity (signal strength or power flux density in watts per square meter) as the actual source antenna at a distant receiver located in the direction of the antenna's strongest beam (main lobe).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_demand">Effective demand</a></td>
      <td>In economics, effective demand (ED) in a market is the demand for a product or service which occurs when purchasers are constrained in a different market.  It contrasts with notional demand, which is the demand that occurs when purchasers are not constrained in any other market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_mass">Effective mass</a></td>
      <td>In solid state physics, a particle's effective mass (often denoted \n  \n    \n      \n        \n          m\n          \n            ∗\n          \n        \n      \n    \n    {\textstyle m^{*}}\n  ) is the mass that it seems to have when responding to forces, or the mass that it seems to have when interacting with other identical particles in a thermal distribution. One of the results from the band theory of solids is that the movement of particles in a periodic potential, over long distances larger than the lattice spacing, can be very different from their motion in a vacuum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_interest_rate">Effective interest rate</a></td>
      <td>The effective interest rate (EIR), effective annual interest rate, annual equivalent rate (AER) or simply effective rate is the interest rate on a loan or financial product restated from the nominal interest rate and expressed as the equivalent interest rate if compound interest was payable annually in arrears.\nIt is used to compare the interest rates between loans with different compounding periods, such as weekly, monthly, half-yearly or yearly.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phase_4">Phase 4</a></td>
      <td>Phase Four of the Marvel Cinematic Universe (MCU) is a group of American superhero films and television series produced by Marvel Studios based on characters that appear in publications by Marvel Comics. Phase Four features all of the Marvel Studios productions set to be released from 2021 through 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bhadla_Solar_Park">Bhadla Solar Park</a></td>
      <td>Bhadla Solar Park is the largest solar park in the world as of 2021, and is spread over a total area of 5,700 hectares (14,000 acres) in Bhadla, Phalodi tehsil, Jodhpur district, Rajasthan, India.The park has a total capacity of 2245 MW. The park had witnessed the lowest bid for solar power in India as of December 2020 at ₹2.44 (3.2¢ US) per kilowatt-hour. In September 2018, Acme Solar announced that it had commissioned India's cheapest solar power: 200 MW at Bhadla.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Delhi_Metro">Delhi Metro</a></td>
      <td>The Delhi Metro is a mass rapid transit (MRT) system serving Delhi and its satellite cities of Ghaziabad, Faridabad, Gurgaon, Noida, Bahadurgarh and Ballabhgarh, in the National Capital Region of India. The network consists of 10 colour-coded lines serving 255 stations with a total length of 348.12 kilometres (216.31 mi).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/All_India_Institutes_of_Medical_Sciences">All India Institutes of Medical Sciences</a></td>
      <td>The All India Institutes of Medical Sciences (AIIMS) is a group of autonomous government public medical universities of higher education under the jurisdiction of Ministry of Health and Family Welfare , Government of India. These institutes have been declared by an Act of Parliament as Institutes of National Importance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Meadow_Lake_Wind_Farm">Meadow Lake Wind Farm</a></td>
      <td>Meadow Lake Wind Farm is an 801.25 megawatt (MW) wind farm near Brookston and Chalmers, Indiana, spreading over portions of White, Jasper, and Benton Counties.  It is owned and operated by EDP Renewables North America.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Landfill">Landfill</a></td>
      <td>A landfill site, also known as a tip, dump, rubbish dump, garbage dump, or dumping ground, is a site for the disposal of waste materials. Landfill is the oldest and most common form of waste disposal, although the systematic burial of the waste with daily, intermediate and final covers only began in the 1940s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/National_Highways_Development_Project">National Highways Development Project</a></td>
      <td>The National Highways Development Project (NHDP) is a project to upgrade, rehabilitate and widen major highways in India to a higher standard. The project was started in 1998 under the leadership of Prime Minister, Atal Bihari Vajpayee.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shenzhen_Metro">Shenzhen Metro</a></td>
      <td>The Shenzhen Metro (simplified Chinese: 深圳地铁; traditional Chinese: 深圳地鐵; pinyin: Shēnzhèn Dìtiě) is the rapid transit system for the city of Shenzhen in Guangdong province, China. Extensions opened on 28 October 2020 put the network at 411 kilometres (255 miles) of trackage, operating on 11 lines with 283 stations.Shenzhen Metro is the 4th longest metro system in China and 8th longest in the world as of that date despite having only opened on 28 December 2004.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>UNITED THERAPEUTICS CORP      ITEM 1A        RISK FACTORS       Forward-Looking Statements       This <font color="blue">Annual Report </font>on Form 10-K contains forward-looking statements made     pursuant to the <font color="blue">safe harbor provisions</font> of Section 21E of the Securities     Exchange Act of 1934 and the Private Securities <font color="blue">Litigation </font>Reform Act of     1995 which are <font color="blue">based on</font> our beliefs and <font color="blue"><font color="blue">expectation</font>s</font> as to future outcomes</td>
    </tr>
    <tr>
      <td>These  statements  include,  among  others, statements relating to the     following:       ·       <font color="blue"><font color="blue">expectation</font>s</font> of revenues and <font color="blue">profitability</font>;       ·       the timing and outcome of <font color="blue">clinical studies</font> and <font color="blue"><font color="blue">regulatory</font> filings</font>;       ·       the <font color="blue">achievement</font> and maintenance of <font color="blue"><font color="blue">regulatory</font> approvals</font>;       ·       the ability to <font color="blue">find alternate sources</font> of supply and <font color="blue">manufacturing</font>     for our products;       ·       the existence and <font color="blue">activities</font> of <font color="blue">competitors</font>;       ·        the  <font color="blue">expectation</font>  not to <font color="blue">pay dividends on <font color="blue">common stock</font></font> in the     <font color="blue">foreseeable future</font>;       ·       the pricing of Remodulin;       ·       the dosing and rate of <font color="blue">patient</font> <font color="blue">consumption</font> of Remodulin;       ·       the impacts of price changes and changes in <font color="blue">patient</font> <font color="blue">consumption</font> of     <font color="blue">Remodulin </font><font color="blue">on future revenues</font>;       ·        the  <font color="blue">expectation</font>  of  <font color="blue">reimbursement</font> by third-party payers for     <font color="blue">intravenous</font> Remodulin;       ·       the timing, impact, materiality and outcome of under-<font color="blue">reimbursement</font>     by third-party payers, such as Medicare;       ·       the timing and outcome of the <font color="blue">Remodulin </font><font color="blue">Phase IV </font><font color="blue">clinical trial</font>;       ·       <font color="blue"><font color="blue">acceptance</font> by</font> the FDA of the <font color="blue">Remodulin </font><font color="blue">Phase IV </font><font color="blue">clinical trial</font>     <font color="blue">interim study</font> report following the 21-<font color="blue">patient</font> <font color="blue">interim <font color="blue">assessment</font></font>s;       ·       any actions that may or may not be taken by the FDA as a result of     the timing and outcome of the <font color="blue">Remodulin </font><font color="blue">Phase IV </font><font color="blue">clinical trial</font>;       ·       the outcome of potential future <font color="blue">warning letters</font> from the FDA and any     actions that may or may not be taken by the FDA as a result of any such     <font color="blue">warning letters</font>;       ·       the rate of physician and <font color="blue">patient</font> <font color="blue">acceptance</font> of our <font color="blue">products as safe</font>     and <font color="blue">effective</font>;       ·        the  <font color="blue">development</font> and sale of <font color="blue">products covered by licenses</font> and     <font color="blue"><font color="blue">assignment</font>s</font>;       ·       the adequacy of our <font color="blue"><font color="blue">intellectual</font> property protections</font>;       ·       the outcome of any <font color="blue">litigation</font> in which we are or <font color="blue">become involved</font>;       ·       the ability of <font color="blue">third parties</font> to develop, market, distribute and sell     our products;       ·       the <font color="blue">composition</font> of our <font color="blue"><font color="blue">management</font> team</font>;       ·       the adequacy of our <font color="blue">insurance coverage</font>;       ·       the ability to obtain financing in the future;       ·       the value of our <font color="blue">common stock</font>;       ·       the funding of <font color="blue"><font color="blue">operations</font> from future revenues</font>;       19     ______________________________________________________________________       ·       the <font color="blue">expectation</font> of <font color="blue">continued profits</font> or losses;       ·        the  expected  impact  of  the <font color="blue">discontinuance</font> of the <font color="blue">HeartBar     </font>line-of-products in January 2006;       ·       <font color="blue"><font color="blue">expectation</font>s</font> concerning milestone and <font color="blue">royalty payments</font> in 2006 and     beyond;       ·       <font color="blue"><font color="blue">expectation</font>s</font> concerning payments of <font color="blue">contractual obligations</font> in all     <font color="blue">future years</font> and their amounts;       ·       the use of net operating <font color="blue">loss <font color="blue">carryforwards</font></font> and business tax credit     <font color="blue">carryforwards</font> and the impact of Section 382 of the <font color="blue">Internal Revenue Code </font>on     their use;       ·       <font color="blue">income tax expenses</font> and benefits in current and <font color="blue">future periods</font>;       ·       the <font color="blue">completion</font> of in-process research and <font color="blue">development</font> projects and     their <font color="blue">impact on</font> our business;       ·       the pace and timing of <font color="blue">enrollment</font> in <font color="blue">clinical trial</font>s;       ·       the <font color="blue">expectation</font>, outcome and timing of new and <font color="blue">continuing <font color="blue">regulatory</font></font>     approvals;       ·       the timing, resubmission, <font color="blue">completion</font> and outcome of the <font color="blue"><font color="blue">application</font>s</font>     for approval of <font color="blue">subcutaneous</font> <font color="blue">Remodulin </font>in Ireland, Spain and the United     Kingdom;       ·       the timing, <font color="blue">completion</font> and outcome of pricing approvals in European     Union countries that approve <font color="blue">subcutaneous</font> Remodulin;       ·       the expected levels and timing of <font color="blue">Remodulin </font>sales;       ·       the adequacy of our resources to <font color="blue">fund <font color="blue">operations</font></font>;       ·        the  timing  and  level of spending to construct a <font color="blue">laboratory</font>     <font color="blue">production <font color="blue">facility</font></font> in Silver Spring, Maryland;       ·       the potential amount of the <font color="blue">minimum residual value guarantee</font> to     Wachovia under the synthetic lease;       ·       events that could occur <font color="blue">upon <font color="blue">termination</font></font> <font color="blue">of the Wachovia </font>synthetic     lease and related <font color="blue"><font color="blue">agreement</font>s</font>;       ·       the <font color="blue">potential impacts</font> of <font color="blue">new accounting standards</font>;       ·        the sale of <font color="blue">common stock</font> at favorable <font color="blue">terms under</font> the primary     <font color="blue">registration statement filed with</font> the <font color="blue">SEC in February </font>2005;       ·       our intent and ability to hold <font color="blue">certain marketable <font color="blue"><font color="blue">investment</font>s</font> until</font>     maturity;       ·       any statements preceded by, followed by or that include the words     “believes,” “expects,” “predicts,” “anticipates,” “intends,” “estimates,”     “should,” “may” or similar <font color="blue">expressions</font>; and       ·       other <font color="blue">statements contained</font> or <font color="blue">incorporated by reference</font> in this     <font color="blue">Annual Report </font>on Form 10-K that are not <font color="blue">historical facts</font></td>
    </tr>
    <tr>
      <td>The statements identified as forward-looking statements may exist in “<font color="blue">Item     </font>7—Management’s Discussion and Analysis of Financial Condition and Results of     Operations”  or  elsewhere  in  this <font color="blue">Annual Report </font>on Form 10-K <font color="blue">These     </font>statements are subject to risks and <font color="blue">uncertainties</font> and our actual results may     <font color="blue">differ materially from</font> anticipated results</td>
    </tr>
    <tr>
      <td>We     undertake <font color="blue">no obligation</font> to publicly update forward-looking statements,     <font color="blue">whether as</font> a result of new information, <font color="blue">future events</font> or otherwise</td>
    </tr>
    <tr>
      <td>Unless  the  context requires otherwise or unless otherwise noted, all     references in this section to “United Therapeutics” and to the “company”,     “we”,  “us”  or  “our”  are <font color="blue">to United Therapeutics </font>Corporation and its     <font color="blue">subsidiaries</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       Actual <font color="blue">consolidated revenues</font> and <font color="blue">net income may</font> be <font color="blue"><font color="blue">different</font> from published</font>     <font color="blue">securities analyst <font color="blue">projections</font></font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">independent securities analysts</font> have <font color="blue">published quarterly</font> and annual     <font color="blue">projections</font>  of  our revenues and profits</td>
    </tr>
    <tr>
      <td>These <font color="blue">projections</font> were made     <font color="blue"><font color="blue">independently</font> by</font> the <font color="blue">securities analysts <font color="blue">based on</font></font> their own analysis</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>estimates are <font color="blue">inherently</font> subject to a degree of <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>Even small <font color="blue">variations</font> in reported revenues and     profits  as  compared to securities analysts’ <font color="blue"><font color="blue">expectation</font>s</font> can lead to     <font color="blue">significant</font> changes in our stock price</td>
    </tr>
    <tr>
      <td>Although we were profitable for <font color="blue">every quarter</font> ended after March 31, 2004, we     <font color="blue">lost money from</font> the date of our inception in 1996 through March 31, 2004</td>
    </tr>
    <tr>
      <td>At     <font color="blue">December </font>31, 2005, our <font color="blue">accumulated deficit</font> was <font color="blue">approximately</font> dlra115dtta3 million</td>
    </tr>
    <tr>
      <td>Factors that could affect <font color="blue">consolidated revenues</font> and <font color="blue">profitability</font> and cause     our  quarterly  and  annual operating results to fluctuate include the     following:       ·       Extent and timing of sales of <font color="blue">Remodulin </font>to <font color="blue"><font color="blue">distributor</font>s</font>;       ·       Levels of <font color="blue">Remodulin </font>inventory held by our <font color="blue"><font color="blue">distributor</font>s</font> and changes     to those <font color="blue">levels from quarter</font> to quarter;       ·       Level of <font color="blue">patient</font> demand for <font color="blue">Remodulin </font>and other products;       ·       Changes in <font color="blue">prescribers</font>’ opinions about Remodulin;       ·       Impact of medical and scientific opinion about our products;       ·        Levels  of  research  and  <font color="blue">development</font>,  selling, general and     <font color="blue">administrative</font> expenses;       ·       Timing of payments to <font color="blue">licensors</font> and corporate partners;       ·       <font color="blue">Retention </font>and growth of <font color="blue">patient</font>s treated with Remodulin;       ·       <font color="blue">Remodulin </font>side effects, including impact of <font color="blue">infusion site pain</font> and     reaction from <font color="blue">subcutaneous</font> use of Remodulin;       ·       Changes in the <font color="blue">current pricing</font> and dosing of Remodulin;       ·       Changes in the length of time that <font color="blue">Remodulin </font>vials may be used by     <font color="blue">patient</font>s;       ·        <font color="blue">Changes  </font>in  the pricing of other <font color="blue">therapies approved</font> for PAH,     including <font color="blue">possible generic <font color="blue"><font color="blue">formulation</font>s</font></font> of other <font color="blue">approved therapies</font>, such as     Flolan, which may be sold in generic form beginning in May 2007;       ·       <font color="blue">Willingness </font>of private insurance companies, <font color="blue">Medicare and Medicaid </font>to     reimburse <font color="blue">Remodulin </font>at <font color="blue">current pricing</font> levels;       ·        Impacts of new <font color="blue">legislation</font> and <font color="blue">regulations</font> and changes to the     <font color="blue">Medicare and Medicaid </font>programs;       ·       The outcome of the <font color="blue">Remodulin </font><font color="blue">Phase IV </font>post-marketing study;       ·       Our ability to maintain <font color="blue">regulatory</font> approval of <font color="blue">Remodulin </font>in the     <font color="blue"><font color="blue">United States</font> </font>and other countries;       ·       <font color="blue">Additional </font><font color="blue"><font color="blue">regulatory</font> approvals</font> for <font color="blue">Remodulin </font>in countries other     than where it is currently sold;       ·       Status and impact of other <font color="blue">approved <font color="blue">competitive</font> products such as</font>     Ventavis, Revatio, Tracleer and Flolan and <font color="blue">investigational</font> <font color="blue">competitive</font>     products such as <font color="blue">ambrisentan</font>, Thelin, Cialis®, Gleevec® and other potential     <font color="blue">investigational</font> <font color="blue">competitive</font> products;       21     ______________________________________________________________________       ·        <font color="blue">Continued </font><font color="blue">performance by current</font> <font color="blue">Remodulin </font><font color="blue"><font color="blue">distributor</font>s</font> under     existing <font color="blue"><font color="blue">agreement</font>s</font>;       ·       Size, scope and outcome of <font color="blue">development</font> efforts for existing and     <font color="blue">additional</font> products;       ·        Future milestone and <font color="blue">royalty payments</font> under license and other     <font color="blue"><font color="blue">agreement</font>s</font>;       ·       Cost, timing and outcomes of <font color="blue">regulatory</font> reviews;       ·       Rate of <font color="blue">technological</font> advances;       ·       Our ability to establish, defend and <font color="blue">enforce <font color="blue">intellectual</font> property</font>     rights;       ·        <font color="blue">Development </font> of <font color="blue">manufacturing</font> resources or the <font color="blue">establishment</font>,     <font color="blue">continuation</font> or <font color="blue">termination</font> of third-party <font color="blue">manufacturing</font> arrangements;       ·       Establishment, <font color="blue">continuation</font> or <font color="blue">termination</font> of third-party clinical     <font color="blue">trial arrangements</font>;       ·       <font color="blue">Development </font>of sales and marketing resources or the <font color="blue">establishment</font>,     <font color="blue">continuation</font> or <font color="blue">termination</font> of third-party sales and <font color="blue">marketing arrangements</font>;       ·        Impact  of  any  <font color="blue">regulatory</font> <font color="blue">restrictions</font> on our marketing and     promotional <font color="blue">activities</font>;       ·        <font color="blue">Recovery  </font>of  goodwill,  <font color="blue">intangible assets</font> and <font color="blue"><font color="blue">investment</font>s</font> in     <font color="blue">affiliates</font>;       ·       <font color="blue">Collection </font>of <font color="blue">accounts</font> receivable and <font color="blue">realization</font> of <font color="blue">inventories</font>;       ·        Risks  <font color="blue">associated with <font color="blue"><font color="blue">acquisition</font>s</font></font>, including the ability to     integrate acquired <font color="blue">businesses</font>;       ·       <font color="blue">Unforeseen </font>expenses;       ·       Actual growth in sales of <font color="blue">telemedicine</font> and <font color="blue">arginine products</font>;       ·       Actual <font color="blue">expenses incurred</font> in <font color="blue">future periods</font>; and       ·       <font color="blue">Completion </font>of <font color="blue">additional</font> <font color="blue"><font color="blue">acquisition</font>s</font> and execution of licensing     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">pharmaceutical</font> products are in <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>We might not     maintain or obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> for our <font color="blue">pharmaceutical</font> products and     may not be able to sell our <font color="blue">pharmaceutical</font> products <font color="blue">commercially</font></td>
    </tr>
    <tr>
      <td>Even if we     sell our products, we may not be profitable and may not be able to sustain     any <font color="blue">profitability</font> we achieve</td>
    </tr>
    <tr>
      <td>We may not <font color="blue"><font color="blue">successfully</font> <font color="blue">compete with</font> established drugs</font> and the companies     that develop and <font color="blue">market them</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> established <font color="blue">drug companies</font> during product <font color="blue">development</font> for,     among other things, funding, access to licenses, expertise, personnel,     <font color="blue">clinical trial</font> <font color="blue">patient</font>s, and third-party collaborators</td>
    </tr>
    <tr>
      <td>We <font color="blue">also <font color="blue">compete with</font></font>     these <font color="blue">companies following approval</font> of our products</td>
    </tr>
    <tr>
      <td>Almost all of these     <font color="blue">competitors</font>  have  <font color="blue">substantially</font>  greater financial, marketing, sales,     <font color="blue">distribution</font> and <font color="blue">technical resources</font>, and more experience in research and     <font color="blue">development</font>, <font color="blue">clinical trial</font>s and <font color="blue">regulatory</font> matters, than we do</td>
    </tr>
    <tr>
      <td>We  are  aware  of <font color="blue">existing treatments</font> that <font color="blue">compete with</font> our products,     <font color="blue">especially</font> in the field of <font color="blue">PAH Patients </font>and doctors may perceive these     <font color="blue">competing product</font>s to be safer, more <font color="blue">effective</font>, more <font color="blue">convenient</font> or less     expensive than Remodulin</td>
    </tr>
    <tr>
      <td>Accordingly, sales of <font color="blue">Remodulin </font>may not increase     or <font color="blue">may even decrease</font> if <font color="blue">doctors prescribe less</font> <font color="blue">Remodulin </font>than they are     <font color="blue">prescribing at present</font></td>
    </tr>
    <tr>
      <td>For the treatment of PAH, we <font color="blue">compete with</font> many <font color="blue">approved products</font> in the     <font color="blue"><font color="blue">United States</font> </font>and worldwide, including the following:       ·       Flolan was the <font color="blue">first product approved by</font> the FDA for treating PAH     and  has  been  marketed  by  <font color="blue">GlaxoSmithKline </font> PLC since 1996</td>
    </tr>
    <tr>
      <td><font color="blue">Generic     </font><font color="blue"><font color="blue">formulation</font>s</font> of Flolan could be available for       22     ______________________________________________________________________       commercial  sale  as early as 2007</td>
    </tr>
    <tr>
      <td>Flolan is delivered by <font color="blue">intravenous</font>     infusion and considered to be an <font color="blue">effective</font> treatment by most PAH experts;       ·       Ventavis was approved in <font color="blue">December </font>2004 in the <font color="blue"><font color="blue">United States</font> </font>and in     <font color="blue">September </font>2003 in Europe</td>
    </tr>
    <tr>
      <td>Ventavis is the <font color="blue">only <font color="blue">prostacyclin</font></font> that has been     approved for <font color="blue">inhalation</font>, whereas <font color="blue">Remodulin </font>is <font color="blue">only currently approved</font> to be     delivered through <font color="blue">intravenous</font> or <font color="blue">subcutaneous</font> infusion</td>
    </tr>
    <tr>
      <td>Ventavis is marketed     by CoTherix, Inc</td>
    </tr>
    <tr>
      <td>in the <font color="blue"><font color="blue">United States</font> </font>and Schering AG in Europe;       ·       Tracleer, the first oral drug to be approved for PAH, is also the     <font color="blue">first drug</font> in its class, <font color="blue">known as <font color="blue"><font color="blue">endothelin</font> receptor <font color="blue">antagonist</font>s</font></font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Tracleer  </font>   </font>was approved in <font color="blue">December </font>2001 in the <font color="blue"><font color="blue">United States</font> </font>and May 2002 in Europe</td>
    </tr>
    <tr>
      <td><font color="blue">Tracleer  </font>is <font color="blue">marketed by</font> Actelion, Ltd</td>
    </tr>
    <tr>
      <td>As an <font color="blue">oral therapy</font>,     Tracleer is a very <font color="blue">convenient</font> therapy; and       ·       Revatio was approved in June 2005 in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Revatio is     also an <font color="blue">oral therapy</font> and is <font color="blue">marketed by</font> Pfizer</td>
    </tr>
    <tr>
      <td>Revatio is a <font color="blue">different</font>     <font color="blue">formulation</font> of the very <font color="blue">successful drug</font> Viagra and is the <font color="blue">first drug</font> in its     class, known as PDE-5 <font color="blue">inhibitors</font>, to be approved for PAH       Doctors may reduce the dose of <font color="blue">Remodulin </font>given to their <font color="blue">patient</font>s if they     prescribe our <font color="blue">competitors</font>’ products in <font color="blue"><font color="blue">combination</font> with</font> Remodulin</td>
    </tr>
    <tr>
      <td>Many companies are marketing and developing <font color="blue">products containing arginine</font>     that  compete  with our <font color="blue">arginine product line</font></td>
    </tr>
    <tr>
      <td>Many local and regional     <font color="blue">competitors</font> and a few national <font color="blue">competitors</font> provide cardiac Holter and event     monitoring services and systems that <font color="blue">compete with</font> our <font color="blue">telemedicine</font> products</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">drug companies</font> are <font color="blue">pursuing treatments</font> for ovarian and other     cancers and <font color="blue">hepatitis</font> that will <font color="blue">compete with</font> any products we may develop     from our <font color="blue"><font color="blue">immunotherapeutic</font> monoclonal <font color="blue">antibody platform</font></font> and <font color="blue">glycobiology</font>     <font color="blue">antiviral <font color="blue">agents platform</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Discoveries </font>or <font color="blue">development</font>s of new <font color="blue">technologies</font> by others may make our     <font color="blue">products obsolete</font> or less useful</td>
    </tr>
    <tr>
      <td>Other <font color="blue">companies may</font> make <font color="blue">discoveries</font> or <font color="blue">introduce <font color="blue">new products</font></font> that render     all or some of our <font color="blue">technologies</font> and <font color="blue">products obsolete</font> or not <font color="blue">commercially</font>     viable</td>
    </tr>
    <tr>
      <td><font color="blue">Researchers </font>are <font color="blue">continually</font> making new <font color="blue">discoveries</font> that may lead to     new <font color="blue">technologies</font> to treat the diseases for which our products are intended</td>
    </tr>
    <tr>
      <td>In addition, alternative approaches to treating chronic diseases, such as     gene  therapy, may make our <font color="blue">products obsolete</font> or non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td><font color="blue">Other     </font><font color="blue">investigational</font>  therapies  for  PAH could be used in <font color="blue"><font color="blue">combination</font> with</font>     Remodulin</td>
    </tr>
    <tr>
      <td>If this happens, <font color="blue">doctors may reduce</font> the dose of <font color="blue">Remodulin </font>given     to their <font color="blue">patient</font>s</td>
    </tr>
    <tr>
      <td>This could result in less <font color="blue">Remodulin </font>being <font color="blue">used by such</font>     <font color="blue">patient</font>s and, hence, reduced sales of Remodulin</td>
    </tr>
    <tr>
      <td>We are aware of <font color="blue">investigational</font> products being developed for the treatment     of PAH with which our <font color="blue">products may</font> have to compete</td>
    </tr>
    <tr>
      <td>Our  Remodulin-based <font color="blue">products may</font> have to <font color="blue">compete with</font> <font color="blue">investigational</font>     <font color="blue">products currently</font> being developed by other companies, including:       ·         Sitaxentan   (Thelin)   is   being   developed  by  Encysive     Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>worldwide for the treatment of <font color="blue">PAH Encysive </font>has     completed  testing  of Thelin, an oral tablet, and, <font color="blue">based on</font> favorable     results, has filed for approval with <font color="blue">the Food and Drug Administration </font>in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">application</font> is currently being reviewed</td>
    </tr>
    <tr>
      <td>If approved,     Thelin  would  become  the <font color="blue">second drug available</font> in the class known as     <font color="blue"><font color="blue">endothelin</font> receptor <font color="blue">antagonist</font>s</font>;       ·       <font color="blue">Ambrisentan </font>is being developed by Myogen, Inc</td>
    </tr>
    <tr>
      <td>for the treatment of     PAH Ambrisentan, an oral tablet, is still in clinical testing and is also     an <font color="blue">endothelin</font> receptor <font color="blue">antagonist</font>;       ·       Cialis® is an <font color="blue">approved oral treatment</font> for <font color="blue">erectile dysfunction</font> and     is currently <font color="blue">marketed by</font> Lilly ICOS LLC, a joint venture of Eli Lilly &amp;     Company and ICOS Corporation</td>
    </tr>
    <tr>
      <td>Cialis is currently being studied in <font color="blue">patient</font>s     with PAH; and is in the same class of drugs as Revatio;       23     ______________________________________________________________________       ·       Gleevec® is an <font color="blue">approved oral treatment</font> for <font color="blue">chronic myeloid leukemia</font>     (a  cancer  of the blood and <font color="blue">bone marrow</font>) and is currently <font color="blue">marketed by</font>     <font color="blue">Novartis Pharmaceuticals Corporation</font></td>
    </tr>
    <tr>
      <td>Recently, <font color="blue">researchers</font> experienced in     PAH have conducted studies of Gleevec and believe that it may be <font color="blue">effective</font>     in treating PAH;       ·        PRX-08066,  a  serotonin receptor 5-HT2B <font color="blue">antagonist</font>, is being     developed by Predix Pharmaceuticals Holdings, Inc, as an oral tablet for     the treatment of <font color="blue">PAH Two Phase I </font><font color="blue">clinical trial</font>s of PRX-08066 are being     conducted in <font color="blue">healthy volunteers</font>;       ·       PulmoLAR™ is being developed by PR Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>It is a     once-a-month injectible which contains a metabolite of estradiol and has     been  shown  in animal and <font color="blue">cell models</font> to address the <font color="blue">key pathological</font>     <font color="blue">processes associated with</font> PAH; and       ·       Aviptadil, an inhaled <font color="blue">formulation</font> of vasoactive intestinal protein,     is being developed by <font color="blue">mondoBIOTECH</font> Holding SA, for the treatment of PAH       There may be <font color="blue">additional</font> drugs in <font color="blue">development</font> for PAH and there may also be     <font color="blue">currently <font color="blue">approved drugs</font></font> that may be <font color="blue">effective</font> in treating the disease</td>
    </tr>
    <tr>
      <td>If     any of these drugs in <font color="blue">development</font> or other <font color="blue">currently <font color="blue">approved drugs</font></font> are used     to treat PAH, sales of <font color="blue">Remodulin </font>may fall</td>
    </tr>
    <tr>
      <td>If third-party payers will not reimburse <font color="blue">patient</font>s for our <font color="blue"><font color="blue">drug product</font>s</font> or     if third-party payers limit the amount of <font color="blue">reimbursement</font>, our <font color="blue">sales will</font>     suffer</td>
    </tr>
    <tr>
      <td>Our  commercial success depends heavily on third-party payers, such as     Medicare, Medicaid and private insurance companies, agreeing to reimburse     <font color="blue">patient</font>s for the costs of our <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>These third-party     payers frequently challenge the pricing of new and <font color="blue">expensive drugs</font>, and it     may be <font color="blue">difficult</font> for <font color="blue">pharmacies selling</font> <font color="blue">Remodulin </font>to convince these payers     to  reimburse  <font color="blue">patient</font>s  for  the cost of Remodulin</td>
    </tr>
    <tr>
      <td><font color="blue">Remodulin </font>and the     <font color="blue">associated infusion pump</font> and supplies are very expensive</td>
    </tr>
    <tr>
      <td>We believe our     <font color="blue">investigational</font>  products,  if  approved, will also be very expensive</td>
    </tr>
    <tr>
      <td>Presently,  most  third-party payers, including Medicare and Medicaid,     reimburse <font color="blue">patient</font>s for the cost of <font color="blue">Remodulin </font>therapy</td>
    </tr>
    <tr>
      <td>In the past, <font color="blue">Medicare     </font>has not reimbursed the full cost of the therapy for some <font color="blue">patient</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Beginning     </font>on January 1, 2007, the <font color="blue">Medicare Modernization Act </font>requires that we and the     <font color="blue">Centers  </font>for  <font color="blue">Medicare and Medicaid </font>Services negotiate a new price for     Remodulin</td>
    </tr>
    <tr>
      <td>Third-party  payers  may  not approve our <font color="blue">new products</font> for     <font color="blue">reimbursement</font> or continue to approve <font color="blue">Remodulin </font>for <font color="blue">reimbursement</font>, or may     seek to reduce the amount of <font color="blue">reimbursement</font> for <font color="blue">Remodulin </font><font color="blue">based on</font> changes in     pricing of other therapies for PAH, including <font color="blue">possible generic <font color="blue"><font color="blue">formulation</font>s</font></font>     of other <font color="blue">approved therapies</font>, such as Flolan, which may be sold in generic     form beginning in May 2007</td>
    </tr>
    <tr>
      <td>If third-party payers do not approve a product     of ours for <font color="blue">reimbursement</font> or limit the amount of <font color="blue">reimbursement</font>, <font color="blue">sales will</font>     suffer, as <font color="blue">patient</font>s will opt for a <font color="blue">competing product</font> that is approved for     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">third parties</font> to develop, market, distribute and sell most of our     products and those <font color="blue">third parties</font> may not perform</td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">currently marketing products</font> in three of our <font color="blue">five therapeutic</font>     platforms: <font color="blue">Remodulin </font>in our <font color="blue">prostacyclin</font> analog platform, the products     containing arginine in our arginine <font color="blue"><font color="blue">formulation</font>s</font> platform, and CardioPAL     <font color="blue">cardiac event monitors</font> and Holter monitors in our <font color="blue">telemedicine</font> platform</td>
    </tr>
    <tr>
      <td>We     do not have the ability to <font color="blue">independently</font> conduct <font color="blue">clinical studies</font>, obtain     <font color="blue"><font color="blue">regulatory</font> approvals</font>, market, distribute or sell most of our products and     intend to rely <font color="blue">substantially</font> on experienced <font color="blue">third parties</font> to perform all of     those functions</td>
    </tr>
    <tr>
      <td>We may not locate acceptable <font color="blue">contractors</font> or <font color="blue">enter into</font>     favorable <font color="blue"><font color="blue">agreement</font>s</font> with them</td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> do not <font color="blue">successfully</font> carry     out their <font color="blue">contractual duties</font> or meet expected <font color="blue">deadlines</font>, we might not be     able to obtain <font color="blue"><font color="blue">marketing approval</font>s</font> and sell our products</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       <font color="blue">Medtronic MiniMed </font>is our <font color="blue">exclusive partner</font> for the <font color="blue">subcutaneous</font> delivery of     <font color="blue">Remodulin </font> using  the MiniMed <font color="blue">microinfusion</font> device for PAH We rely on     Medtronic MiniMed’s experience, expertise and performance</td>
    </tr>
    <tr>
      <td>Any <font color="blue">disruption</font> in     the supply to PAH <font color="blue">patient</font>s of MiniMed’s <font color="blue">microinfusion</font> device could delay or     prevent <font color="blue">patient</font>s from initiating or continuing <font color="blue">Remodulin </font>therapy, which     could  <font color="blue">adversely</font>  affect  our  revenues</td>
    </tr>
    <tr>
      <td>Similarly, we rely on Accredo     Therapeutics, Inc</td>
    </tr>
    <tr>
      <td>),  <font color="blue">CuraScript  </font>(a  wholly  owned subsidiary of Express     Scripts, Inc</td>
    </tr>
    <tr>
      <td>and  formerly  Priority  Healthcare  Corporation)  and     Caremark, Inc</td>
    </tr>
    <tr>
      <td>to  market,  distribute,  and  sell  <font color="blue">Remodulin </font> in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Accredo, CuraScript and Caremark are <font color="blue">also responsible</font> for     convincing  third-party  payers  to reimburse <font color="blue">patient</font>s for the cost of     Remodulin, which is very expensive</td>
    </tr>
    <tr>
      <td>If our partners and <font color="blue">contractors</font> do not     achieve acceptable <font color="blue">profit margins</font>, they may not continue to distribute our     products</td>
    </tr>
    <tr>
      <td>If our partners in the <font color="blue"><font color="blue">United States</font> </font>and <font color="blue">internationally</font> are     <font color="blue">unsuccessful</font> in their efforts, our <font color="blue">revenues will suffer</font></td>
    </tr>
    <tr>
      <td>During 2005, two of our <font color="blue">Remodulin </font><font color="blue"><font color="blue">distributor</font>s</font> in the <font color="blue"><font color="blue">United States</font> </font>were     sold to <font color="blue">larger companies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">distributor</font>s</font> continue to purchase <font color="blue">Remodulin </font>    from us and distribute it</td>
    </tr>
    <tr>
      <td>Together, they account for most of the <font color="blue">Remodulin </font>    sales we have made thus far</td>
    </tr>
    <tr>
      <td>When these <font color="blue"><font color="blue">distributor</font>s</font> were <font color="blue">independently</font>     managed, <font color="blue">distribution</font> of <font color="blue">Remodulin </font>was more <font color="blue">significant</font> to the <font color="blue"><font color="blue">distributor</font>s</font>,     because they were much smaller</td>
    </tr>
    <tr>
      <td>Now, <font color="blue">Remodulin </font>is much less <font color="blue">significant</font> to     the <font color="blue"><font color="blue">distributor</font>s</font> because they are divisions or <font color="blue">subsidiaries</font> of multi-billion     <font color="blue">dollar companies</font></td>
    </tr>
    <tr>
      <td>It is possible, therefore, that these <font color="blue"><font color="blue">distributor</font>s</font> may     <font color="blue">devote fewer resources</font> to the <font color="blue">distribution</font> of Remodulin</td>
    </tr>
    <tr>
      <td>If so, this may     <font color="blue">negatively impact</font> our sales</td>
    </tr>
    <tr>
      <td>If we cannot maintain <font color="blue"><font color="blue">regulatory</font> approvals</font> for our products, we <font color="blue">cannot sell</font>     those products and our <font color="blue">revenues will suffer</font></td>
    </tr>
    <tr>
      <td>The process of obtaining and maintaining <font color="blue"><font color="blue">regulatory</font> approvals</font> for new drugs     is  lengthy,  expensive  and uncertain</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font>, <font color="blue">distribution</font>,     <font color="blue">advertising</font>  and  marketing of these products are subject to extensive     regulation</td>
    </tr>
    <tr>
      <td>Any <font color="blue">new <font color="blue">product approvals</font></font> we receive in the <font color="blue">future could</font> include     <font color="blue">significant</font> <font color="blue">restrictions</font> on the use or marketing of the product</td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font>approvals,  if  granted,  can  be withdrawn for failure to <font color="blue">comply with</font>     <font color="blue">regulatory</font> <font color="blue">requirement</font>s (including those relating to misleading <font color="blue">advertising</font>     and  we  already  received  <font color="blue">one warning letter from</font> the FDA related to     <font color="blue">advertising</font>  in  2005  which  was <font color="blue">resolved satisfactorily</font>) or upon the     occurrence  of <font color="blue">adverse events following commercial introduction</font> of the     products</td>
    </tr>
    <tr>
      <td>The FDA has approved <font color="blue">Remodulin </font>for the treatment of PAH in <font color="blue">patient</font>s with     Class II-IV symptoms to <font color="blue">diminish symptoms associated with exercise</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>approval is subject to the <font color="blue">requirement</font> that we perform a post-marketing     Phase  IV  clinical  study  to <font color="blue">further assess</font> the <font color="blue">clinical benefits</font> of     Remodulin</td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font>FDA approval of <font color="blue">Remodulin </font>is subject to the diligent     and timely <font color="blue">completion</font> of that trial, as well as its outcome</td>
    </tr>
    <tr>
      <td>The 39-<font color="blue">patient</font>     <font color="blue">Phase IV </font><font color="blue">clinical trial</font> was required to have been one-half enrolled by     June 2004 and to have <font color="blue">been fully enrolled by</font> June 2005</td>
    </tr>
    <tr>
      <td>The <font color="blue">final study</font>     report was required to have <font color="blue">been submitted</font> in <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>Twenty two     <font color="blue">patient</font>s were enrolled in the <font color="blue">Phase IV </font>trial</td>
    </tr>
    <tr>
      <td><font color="blue">Enrolling </font><font color="blue">patient</font>s in this     study is <font color="blue">difficult</font>, in part because it <font color="blue">involves randomizing</font> some of the     <font color="blue">patient</font>s to <font color="blue">placebo despite</font> the fact that <font color="blue">approved drugs</font> were available for     these <font color="blue">patient</font>s</td>
    </tr>
    <tr>
      <td>We did not enroll the <font color="blue">Phase IV </font><font color="blue">trial within</font> the time frame     <font color="blue">specified by</font> the FDA, and therefore are at risk <font color="blue">of the FDA </font>at any time     <font color="blue">instituting</font> a public hearing to <font color="blue">withdraw <font color="blue">marketing approval</font></font> for Remodulin</td>
    </tr>
    <tr>
      <td>The FDA permitted an <font color="blue">interim <font color="blue">assessment</font></font> and <font color="blue">opportunity</font> to terminate the     <font color="blue">Phase IV </font>study after only 21 <font color="blue">patient</font>s completed the study</td>
    </tr>
    <tr>
      <td>In July 2005, the     first  21  <font color="blue">patient</font>s  completed  the study and we performed the interim     <font color="blue">assessment</font></td>
    </tr>
    <tr>
      <td>The  results of the <font color="blue">interim <font color="blue">assessment</font></font>, as analyzed by an     <font color="blue">independent statistician</font>, were positive</td>
    </tr>
    <tr>
      <td>Specifically, 13 of 14 <font color="blue">patient</font>s (93prca) in the <font color="blue">Remodulin </font>arm were     able to <font color="blue">successfully</font> transition from Flolan and complete the study without     the need to institute rescue therapy, compared to only 1 of 7 <font color="blue">patient</font>s (14prca)     in the <font color="blue">placebo arm</font></td>
    </tr>
    <tr>
      <td>Based on this positive outcome, we have submitted the     <font color="blue">interim study</font> results to the FDA and have requested <font color="blue">permission</font> to end the     <font color="blue">Phase IV </font>clinical       25     ______________________________________________________________________       study in <font color="blue">satisfaction</font> of our <font color="blue">Phase IV </font><font color="blue">commitments</font></td>
    </tr>
    <tr>
      <td>By <font color="blue"><font color="blue">agreement</font> with</font> the     FDA, <font color="blue">enrollment</font> in the <font color="blue">Phase IV </font><font color="blue">clinical study</font> was <font color="blue">suspended pending</font> FDA     review and <font color="blue">acceptance</font> of the <font color="blue">interim study</font> results</td>
    </tr>
    <tr>
      <td>We  do not know how long the FDA will take to review the <font color="blue">interim study</font>     results, and we <font color="blue">cannot predict</font> the outcome of the review</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>does     not accept the <font color="blue">interim study</font> results or does not <font color="blue">agree with</font> our <font color="blue">assessment</font>     of  the interim results, we <font color="blue">would still</font> be required to <font color="blue">comply with</font> the     FDA-approved protocol for the <font color="blue">Phase IV </font><font color="blue">clinical study</font>, including enrolling     39 <font color="blue">patient</font>s  in  the  study  and  submitting the <font color="blue">final study</font> report by     <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>The FDA could, among other things, grant an extension of time     to continue to enroll the trial, or institute a public hearing to withdraw     <font color="blue">marketing approval</font> for Remodulin</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely heavily on sales</font> of Remodulin</td>
    </tr>
    <tr>
      <td>During the year ended <font color="blue">December </font>31,     2005, our <font color="blue">Remodulin </font><font color="blue">sales accounted</font> for 94 percent of our <font color="blue">total revenues</font></td>
    </tr>
    <tr>
      <td>If     approvals are withdrawn for a product, we <font color="blue">cannot sell</font> that product and our     <font color="blue">revenues will suffer</font></td>
    </tr>
    <tr>
      <td>In addition, if <font color="blue">product approvals</font> are withdrawn,     <font color="blue">governmental <font color="blue">authorities</font> could seize</font> our products or force us to recall our     products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> not be <font color="blue">commercially</font> successful because physicians and     <font color="blue">patient</font>s may not <font color="blue">accept them</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">regulatory</font> <font color="blue">authorities</font> approve our products, these <font color="blue">products may</font> not     be <font color="blue">commercially</font> successful</td>
    </tr>
    <tr>
      <td>We expect that most of our products, including     Remodulin, which is <font color="blue">already approved by</font> the FDA, will be very expensive</td>
    </tr>
    <tr>
      <td>Patient <font color="blue">acceptance</font> of and demand for our products will depend largely on the     <font color="blue">following factors</font>:       ·       <font color="blue">Acceptance </font><font color="blue">by physicians</font> and <font color="blue">patient</font>s of our <font color="blue">products as safe</font> and     <font color="blue">effective</font> therapies;       ·       <font color="blue">Willingness </font>of payers to reimburse and the level of <font color="blue">reimbursement</font> of     drug and treatment costs by third-party payers such as Medicare, Medicaid     and private insurance companies;       ·       Safety, efficacy, pricing and convenience of <font color="blue">alternative products</font>;       ·       <font color="blue">Convenience </font>and ease of <font color="blue">administration</font> of our products; and       ·        <font color="blue">Prevalence  </font>and  severity of side effects associated with our     products, including the <font color="blue">infusion site pain</font> and reaction associated with the     use of <font color="blue">subcutaneous</font> <font color="blue">Remodulin </font>and the potential for <font color="blue">infections associated</font>     with <font color="blue">intravenous</font> Remodulin</td>
    </tr>
    <tr>
      <td>We have limited experience with <font color="blue">manufacturing</font> and depend on <font color="blue">third parties</font>,     who may not perform, to synthesize and <font color="blue">manufacture</font> many of our products</td>
    </tr>
    <tr>
      <td>Prior to our 1999 <font color="blue">acquisition</font> of SynQuest, Inc, a company that <font color="blue">manufacture</font>d     <font color="blue">treprostinil</font>, the bulk active ingredient in Remodulin, we had no experience     with <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>Presently, commercial <font color="blue">treprostinil</font> is being <font color="blue">manufacture</font>d     <font color="blue">only by us</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">third parties</font> for the <font color="blue">manufacture</font> of all our products     other than <font color="blue">treprostinil</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">Baxter Healthcare Corporation </font>for the     <font color="blue">formulation</font> of <font color="blue">Remodulin </font>from <font color="blue">treprostinil</font></td>
    </tr>
    <tr>
      <td>We rely on Cardinal Health, Inc</td>
    </tr>
    <tr>
      <td>for <font color="blue">stability studies on</font> Remodulin, the <font color="blue">formulation</font> of <font color="blue">treprostinil</font> for     <font color="blue">inhalation</font> use, and analyses of other products that we are developing</td>
    </tr>
    <tr>
      <td>We     rely  on  MSI of Central Florida, Inc</td>
    </tr>
    <tr>
      <td>to <font color="blue">manufacture</font> our <font color="blue">telemedicine</font>     devices</td>
    </tr>
    <tr>
      <td>We rely on other <font color="blue">manufacture</font>rs to make our <font color="blue">investigational</font> drugs     for use in trials</td>
    </tr>
    <tr>
      <td>Although there are a limited number of companies that     <font color="blue">could replace each</font> of these suppliers, we believe that other <font color="blue">suppliers could</font>     provide similar services and materials</td>
    </tr>
    <tr>
      <td>A change in suppliers, however,     could cause a delay in <font color="blue">distribution</font> of <font color="blue">Remodulin </font>and other products, and in     the conduct of <font color="blue">clinical trial</font>s and commercial launch, which would <font color="blue">adversely</font>     affect our research and <font color="blue">development</font> efforts and <font color="blue">future sales efforts</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">manufacturing</font> strategy presents the <font color="blue">following risks</font>:       ·       The <font color="blue">manufacturing</font> processes for some of our products have not been     tested in quantities needed for <font color="blue">commercial sales</font>;       26     ______________________________________________________________________       ·       Delays in scale-up to commercial quantities could delay clinical     studies, <font color="blue">regulatory</font> <font color="blue">submissions</font> and <font color="blue">commercialization</font> of our products;       ·        A  long lead time is needed to <font color="blue">manufacture</font> Remodulin, and the     <font color="blue">manufacturing</font> process is complex;       ·       We and the <font color="blue">manufacture</font>rs of our products are subject to the FDA’s     good <font color="blue">manufacturing</font> practices <font color="blue">regulations</font> and similar foreign standards, and     although  we  control  <font color="blue">compliance issues with respect</font> to synthesis and     <font color="blue">manufacturing</font> conducted internally, we do not have <font color="blue">control over compliance</font>     with these <font color="blue">regulations</font> by our third-party <font color="blue">manufacture</font>rs;       ·       Even if we and the <font color="blue">manufacture</font>rs of our products <font color="blue">comply with</font> the     FDA’s  good  <font color="blue">manufacturing</font>  practices  <font color="blue">regulations</font> and similar foreign     standards, the sterility and quality of the products being <font color="blue">manufacture</font>d may     be deficient</td>
    </tr>
    <tr>
      <td>If this occurred, <font color="blue"><font color="blue">such products</font> would</font> not be available for     sale or use;       ·       If we have to change to another <font color="blue">manufacturing</font> contractor or abandon     our own <font color="blue">manufacturing</font> <font color="blue">operations</font>, the FDA and comparable foreign <font color="blue">regulators</font>     would  require  new  testing  and  compliance <font color="blue">inspections</font>, and the new     <font color="blue">manufacture</font>r would have to be educated in the processes <font color="blue">necessary</font> for the     production of the <font color="blue">affected product</font>;       ·       We may not be able to develop or <font color="blue">commercialize</font> our products, other     than  Remodulin,  as planned or at all and will have to <font color="blue">rely solely on</font>     internal <font color="blue">manufacturing</font> capacity;       ·       We intend to transfer all of our drug <font color="blue">laboratory</font> <font color="blue">operations</font> to the     Silver Spring, Maryland <font color="blue"><font color="blue">facility</font> currently</font> being built, and <font color="blue">such transfer</font>     could result in <font color="blue">manufacturing</font> inefficiencies or delays because the building,     equipment and many of the employees being <font color="blue">deployed there will</font> be new to the     process of making our products</td>
    </tr>
    <tr>
      <td>Additionally, the FDA and comparable foreign     <font color="blue">regulators</font> will require new testing and compliance <font color="blue">inspections</font> and this     could result in delays;       ·       The supply of raw and <font color="blue">advanced materials</font> and <font color="blue"><font color="blue">components</font> used</font> in the     <font color="blue">manufacture</font> of <font color="blue">Remodulin </font>and other <font color="blue">products may</font> be interrupted, <font color="blue">which could</font>     delay the <font color="blue">manufacture</font> and <font color="blue">subsequent sale</font> of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Any proposed     <font color="blue">substitute materials</font> and <font color="blue">components</font> are subject to <font color="blue">approval by</font> the FDA     before  any  <font color="blue">manufacture</font>d  product can be sold</td>
    </tr>
    <tr>
      <td>The timing of such FDA     approvals is <font color="blue">difficult</font> to predict and <font color="blue">approvals may</font> not be timely obtained;       ·        <font color="blue">Without  </font>substantial  experience in operating a <font color="blue">manufacturing</font>     <font color="blue">facility</font>, we may not be able to <font color="blue">successfully</font> <font color="blue">manufacture</font> <font color="blue">Remodulin </font>without a     third-party <font color="blue">manufacture</font>r; and       ·       We may not have <font color="blue">intellectual</font> property rights, or may have to share     <font color="blue">intellectual</font>  property  rights,  to  many  of  the <font color="blue">improvements</font> in the     <font color="blue">manufacturing</font> processes or new <font color="blue">manufacturing</font> processes for our <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Any of these factors could delay <font color="blue">clinical studies</font> or <font color="blue">commercialization</font> of     our  products,  entail  higher  costs  and, result in our <font color="blue">inability</font> to     <font color="blue">effective</font>ly sell our products</td>
    </tr>
    <tr>
      <td>If our products fail in <font color="blue">clinical studies</font>, we will not be able to obtain or     maintain  FDA and foreign approvals and will not be able to sell those     products</td>
    </tr>
    <tr>
      <td>In order to sell our <font color="blue">pharmaceutical</font> products, we must receive <font color="blue">regulatory</font>     approvals</td>
    </tr>
    <tr>
      <td>To obtain those approvals, we must conduct <font color="blue">clinical studies</font>     <font color="blue">demonstrating</font> that the <font color="blue">drug product</font>, including its delivery mechanism, is     safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>If we cannot obtain <font color="blue">approval from</font> the FDA for a product,     that <font color="blue">product cannot</font> be sold, and our <font color="blue">revenues will suffer</font></td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       We  recently  conducted a <font color="blue">Phase IV </font><font color="blue">clinical study</font> for Remodulin</td>
    </tr>
    <tr>
      <td>For a     description of the status of this <font color="blue">Phase IV </font>study, see our discussion above     under “Factors that may affect United Therapeutics—If we cannot maintain     <font color="blue"><font color="blue">regulatory</font> approvals</font> for our products, we <font color="blue">cannot sell</font> those products and our     <font color="blue">revenues will suffer</font></td>
    </tr>
    <tr>
      <td>” We have initiated a Phase II/III <font color="blue">clinical study</font> of an     inhaled  <font color="blue">formulation</font>  of  <font color="blue">treprostinil</font>  and Phase I studies of an oral     <font color="blue">formulation</font> of Remodulin</td>
    </tr>
    <tr>
      <td>Our lead <font color="blue">glycobiology</font> antiviral agent, UT-231B,     recently  completed a Phase II, proof-of-concept study</td>
    </tr>
    <tr>
      <td>In that trial,     UT-231B did not demonstrate efficacy against <font color="blue">hepatitis</font> C in a population of     <font color="blue">patient</font>s  that  <font color="blue">previously</font>  <font color="blue">failed conventional treatments</font></td>
    </tr>
    <tr>
      <td>We are now     <font color="blue">conducting <font color="blue">preclinical testing</font></font> of <font color="blue">additional</font> <font color="blue">glycobiology</font> drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also currently conducting two</font> <font color="blue">Phase III </font><font color="blue">pivotal studies</font> of OvaRex for     the  treatment  of ovarian cancer</td>
    </tr>
    <tr>
      <td>We are still completing or planning     pre-<font color="blue">clinical studies</font> for our other products</td>
    </tr>
    <tr>
      <td>In  the  past,  several  of our product <font color="blue">candidates</font> have failed or been     <font color="blue">discontinued</font>  at  various  stages  in the product <font color="blue">development</font> process,     including, but not limited to: <font color="blue">beraprost</font>, <font color="blue">which failed</font> in <font color="blue">Phase III </font>testing     for <font color="blue">early stage peripheral vascular disease</font>; Ketotop, <font color="blue">which failed</font> in Phase     III testing for <font color="blue">osteoarthritis</font> of the knee; and UT-77, <font color="blue">which failed</font> in Phase     II testing for <font color="blue">chronic obstructive pulmonary disease</font></td>
    </tr>
    <tr>
      <td>Also, the length of     time that it takes for us to complete <font color="blue">clinical trial</font>s and obtain <font color="blue">regulatory</font>     approval for product marketing has in the <font color="blue">past varied by product</font> and by the     <font color="blue">intended use</font> of a product</td>
    </tr>
    <tr>
      <td>We expect that this <font color="blue">will likely</font> be the case with     future  product <font color="blue">candidates</font> and we <font color="blue">cannot predict</font> the length of time to     complete <font color="blue">necessary</font> <font color="blue">clinical trial</font>s and obtain <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>Our ongoing and planned <font color="blue">clinical studies</font> might be delayed or halted for     <font color="blue">various reasons</font>, including:       ·       The drug is not <font color="blue">effective</font>, or physicians think that the drug is not     <font color="blue">effective</font>;       ·       Patients do not enroll in the <font color="blue">studies at</font> the rate we expect;       ·       Patients experience severe side <font color="blue">effects during treatment</font>, including     site pain;       ·       Other <font color="blue">investigational</font> or <font color="blue">approved therapies</font> are viewed as more     <font color="blue">effective</font> or <font color="blue">convenient</font> <font color="blue">by physicians</font> or <font color="blue">patient</font>s;       ·       Patients die during the <font color="blue">clinical study</font> because their disease is too     advanced or because they experience <font color="blue">medical problems</font> that are not related to     the drug being studied;       ·       Drug supplies are not available or suitable for use in the studies;     and       ·       The results of <font color="blue">preclinical testing</font> cause delays in <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>In addition, the FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> have substantial     <font color="blue">discretion</font>  in  the  approval  process</td>
    </tr>
    <tr>
      <td>The FDA and foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font> may not agree that we have <font color="blue">demonstrated</font> that our products are     safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate compliance program cannot guarantee</font> that we are in compliance     with all <font color="blue"><font color="blue">potentially</font> <font color="blue">applicable federal</font></font>, state and foreign <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>, <font color="blue">manufacture</font>, <font color="blue">distribution</font>, pricing, sales, marketing, and     <font color="blue">reimbursement</font> of our products, together with our <font color="blue">general <font color="blue">operations</font></font>, are     subject to extensive federal, state and <font color="blue">foreign regulation</font></td>
    </tr>
    <tr>
      <td>While we have     developed and instituted corporate compliance programs, we <font color="blue">cannot assure</font>     that we or our employees are or will be in <font color="blue">compliance with</font> all <font color="blue">potentially</font>     <font color="blue">applicable federal</font>, state and foreign <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font>     any of these <font color="blue">regulations</font>, a range of <font color="blue">actions could</font> result, including, but     not limited to, the <font color="blue">termination</font> of <font color="blue">clinical trial</font>s, the failure to approve a     product candidate, <font color="blue">restrictions</font> on our products or <font color="blue">manufacturing</font> processes,     including withdrawal of our <font color="blue">products from</font> the market, <font color="blue">significant</font> fines,     exclusion  from  <font color="blue">government healthcare programs</font>, or other sanctions or     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________       If  the licenses, <font color="blue"><font color="blue">assignment</font>s</font> and alliance <font color="blue"><font color="blue">agreement</font>s</font> we depend on are     breached or terminated, we would lose our right to develop and sell the     products covered by the licenses, <font color="blue"><font color="blue">assignment</font>s</font> and alliance <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends upon</font> the <font color="blue">acquisition</font>, <font color="blue">assignment</font> and license of drugs     and other products which have <font color="blue">been discovered</font> and initially developed by     others, including Remodulin, all of the products in the <font color="blue">immunotherapeutic</font>     monoclonal  <font color="blue">antibody platform</font>, all of the products in the <font color="blue">glycobiology</font>     antiviral  <font color="blue">agents platform</font>, and all <font color="blue">arginine based products</font></td>
    </tr>
    <tr>
      <td>Under our     product  license <font color="blue"><font color="blue">agreement</font>s</font>, we are <font color="blue">granted certain rights</font> to existing     <font color="blue">intellectual</font> property owned by <font color="blue">third parties</font> subject to the terms of each     license <font color="blue">agreement</font>, whereas <font color="blue">assignment</font> <font color="blue"><font color="blue">agreement</font>s</font> transfer all right, title     and ownership of the <font color="blue">intellectual</font> property to us, subject to the terms of     <font color="blue">each <font color="blue">assignment</font> <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>In addition, we have obtained licenses to other     third-party <font color="blue">technology</font> to conduct our business, including licenses for our     products and an <font color="blue">alliance <font color="blue">agreement</font></font> for the use of the <font color="blue">Medtronic MiniMed </font>    <font color="blue">microinfusion</font> device for the <font color="blue">administration</font> of Remodulin</td>
    </tr>
    <tr>
      <td>In addition, we     may  be required to obtain licenses to other third-party <font color="blue">technology</font> to     <font color="blue">commercialize</font> our early-stage products</td>
    </tr>
    <tr>
      <td>This dependence has the following     risks:       ·        We may not be able to obtain future licenses, <font color="blue"><font color="blue">assignment</font>s</font> and     <font color="blue"><font color="blue">agreement</font>s</font> at a <font color="blue">reasonable cost</font> or at all;       ·       If any of our licenses or <font color="blue"><font color="blue">assignment</font>s</font> are terminated, we will lose     our rights to develop and market the <font color="blue">products covered by such licenses</font> or     <font color="blue"><font color="blue">assignment</font>s</font>;       ·       The licenses and <font color="blue"><font color="blue">assignment</font>s</font> that we hold <font color="blue">generally provide</font> for     <font color="blue">termination</font> by the licensor or assignor in the event we breach the license     or <font color="blue">assignment</font> <font color="blue">agreement</font>, including failing to <font color="blue">pay royalties</font> and other fees     on a <font color="blue">timely basis</font>;       ·        In  the  event that <font color="blue">GlaxoSmithKline </font>(formerly Glaxo Wellcome)     terminates  its  <font color="blue">assignment</font>  <font color="blue">agreement</font>  or Pfizer (formerly Pharmacia)     terminates its license <font color="blue">agreement</font>, we will have <font color="blue">no further rights</font> to utilize     the  assigned  patents  or  <font color="blue">trade secrets</font> to develop and <font color="blue">commercialize</font>     Remodulin</td>
    </tr>
    <tr>
      <td>For  the  year ended <font color="blue">December </font>31, 2005, sales of <font color="blue">Remodulin </font>    accounted   for  <font color="blue">approximately</font>  94  percent  of  our  total  revenues</td>
    </tr>
    <tr>
      <td><font color="blue">GlaxoSmithKline </font>or Pfizer could seek to terminate the <font color="blue">assignment</font> or license,     <font color="blue">respectively</font>, in the event that we fail to <font color="blue">pay royalties</font> <font color="blue">based on</font> sales of     Remodulin; and       ·       If <font color="blue">licensors</font> fail to maintain the <font color="blue">intellectual</font> property licensed or     assigned to us as required by most of our license and <font color="blue">assignment</font> <font color="blue"><font color="blue">agreement</font>s</font>,     we may lose our rights to develop and market some or all of our products and     may  be  forced  to incur substantial <font color="blue">additional</font> costs to maintain the     <font color="blue">intellectual</font> property ourselves or force the licensor or assignor to do so</td>
    </tr>
    <tr>
      <td>Certain license and <font color="blue">assignment</font> <font color="blue"><font color="blue">agreement</font>s</font> relating to our <font color="blue">products may</font>     restrict our ability to develop products in certain countries and/or for     <font color="blue">particular diseases</font> and impose other <font color="blue">restrictions</font> on our freedom to develop     and market our products</td>
    </tr>
    <tr>
      <td>When we acquire, license or receive <font color="blue"><font color="blue">assignment</font>s</font> of drugs and other products     that have <font color="blue">been discovered</font> and initially developed by others, we may receive     <font color="blue">rights only</font> to develop such drugs or products in <font color="blue">certain territories</font> and not     <font color="blue">throughout</font> the world</td>
    </tr>
    <tr>
      <td>For example, we do not have the right to develop     OvaRex and all our other monoclonal antibody <font color="blue">immunotherapies</font> for sale in     most of Europe and the Middle East, and we only have the rights to develop     <font color="blue">beraprost</font> for sale in the <font color="blue"><font color="blue">United States</font> </font>and Canada</td>
    </tr>
    <tr>
      <td>In addition, provisions in our license and <font color="blue">assignment</font> <font color="blue"><font color="blue">agreement</font>s</font> impose     other <font color="blue">restrictions</font> on our freedom to develop and market our products</td>
    </tr>
    <tr>
      <td>For     example, in assigning <font color="blue">Remodulin </font>to us, <font color="blue">GlaxoSmithKline </font>retained an exclusive     option and right of <font color="blue">first refusal</font> to negotiate a license <font color="blue"><font color="blue">agreement</font> with</font> us     if  we  ever  decide to license any aspect of the <font color="blue">commercialization</font> of     <font color="blue">Remodulin </font>anywhere in the world</td>
    </tr>
    <tr>
      <td>Similarly, in <font color="blue">connection</font> with its licenses     of <font color="blue">beraprost</font> to us, Toray Industries, Inc</td>
    </tr>
    <tr>
      <td>obtained a right of <font color="blue">first refusal</font>     from us to develop and sell in Japan up to <font color="blue">two compounds</font> that we develop</td>
    </tr>
    <tr>
      <td>We     also agreed to <font color="blue">provisions giving</font> Toray the <font color="blue">conditional</font> right to approve our     <font color="blue">North American </font><font color="blue">distributor</font>, a <font color="blue">conditional</font>       29     ______________________________________________________________________       restricted non-<font color="blue">competition</font> clause, and to <font color="blue">minimum annual sales</font> in order to     maintain our <font color="blue">exclusive rights</font> to <font color="blue">beraprost</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">restrictions</font> that we have     accepted in our license and <font color="blue">assignment</font> <font color="blue"><font color="blue">agreement</font>s</font> restrict our freedom to     develop and market our products in the future</td>
    </tr>
    <tr>
      <td>If our patent and other <font color="blue">intellectual</font> property protection is inadequate, our     sales and <font color="blue"><font color="blue">profits could</font> suffer</font> or <font color="blue">competitors</font> could force our products     <font color="blue">completely out</font> of the market</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">United States</font> </font>patent for the method of <font color="blue">treating pulmonary hypertension</font>     with <font color="blue">Remodulin </font>is <font color="blue">currently set</font> to expire in October 2014</td>
    </tr>
    <tr>
      <td>The patent for     OvaRex and its method of use are the subject of a <font color="blue">combination</font> of issued     patents and pending <font color="blue"><font color="blue">application</font>s</font> in the <font color="blue"><font color="blue">United States</font> </font>and around the world</td>
    </tr>
    <tr>
      <td>The <font color="blue">issued patents</font> for OvaRex have expiration dates ranging from 2017 to     2020</td>
    </tr>
    <tr>
      <td>We believe that some of the patents to which we have <font color="blue">rights may</font> be     eligible  for  <font color="blue">extensions</font>  of  up to <font color="blue">five years based upon patent term</font>     <font color="blue">restoration</font>  procedures  in  Europe and in the <font color="blue"><font color="blue">United States</font> </font>under the     Waxman-Hatch Act</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may develop products <font color="blue">based on</font> the <font color="blue">same active</font>     <font color="blue">ingredients as</font> our products, including Remodulin, and market those products     after the patents expire, or may design around our existing patents</td>
    </tr>
    <tr>
      <td>If this     happens, our <font color="blue">sales would suffer</font> and our <font color="blue">profits could</font> be <font color="blue">severely impacted</font></td>
    </tr>
    <tr>
      <td>Patents may be issued to others that prevent the <font color="blue">manufacture</font> or sale of our     products</td>
    </tr>
    <tr>
      <td>We may have to license those patents and pay <font color="blue">significant</font> fees or     royalties  to the owners of the patents in order to keep marketing our     products</td>
    </tr>
    <tr>
      <td>We have been granted patents in the <font color="blue"><font color="blue">United States</font> </font>for the synthesis of     Remodulin, but patent <font color="blue"><font color="blue">application</font>s</font> that have been or may be, <font color="blue">filed by us may</font>     not result in the issuance of <font color="blue">additional</font> patents</td>
    </tr>
    <tr>
      <td>The scope of any patent     <font color="blue">issued may</font> not be sufficient to protect our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The laws of foreign     <font color="blue">jurisdictions</font> in which we intend to sell our <font color="blue">products may</font> not protect our     rights to the <font color="blue">same extent as</font> the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">patent protection</font>, we also rely on <font color="blue">trade secrets</font>, <font color="blue">proprietary</font>     know-how and <font color="blue">technology</font> advances</td>
    </tr>
    <tr>
      <td>We <font color="blue">enter into</font> confidentiality <font color="blue"><font color="blue">agreement</font>s</font>     with our employees and others, but these <font color="blue"><font color="blue">agreement</font>s</font> may not be <font color="blue">effective</font> in     protecting our <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>Others may <font color="blue">independently</font> develop     <font color="blue">substantially</font> equivalent <font color="blue">proprietary</font> information or obtain access to our     know-how</td>
    </tr>
    <tr>
      <td>Litigation, which is very expensive, may be <font color="blue">necessary</font> to enforce or defend     our patents or <font color="blue">proprietary</font> rights and may not end favorably for us</td>
    </tr>
    <tr>
      <td>We are     currently a party to pending <font color="blue">litigation</font> against other parties believed to     have violated our patents related to our <font color="blue">arginine products</font> line, and the     validity and <font color="blue">enforceability</font> of the patents related to our <font color="blue">arginine products</font>     is currently being challenged</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also choose</font> to initiate <font color="blue">litigation</font>     against other parties who we come to believe are infringing these patents</td>
    </tr>
    <tr>
      <td>If such <font color="blue">litigation</font> is <font color="blue">unsuccessful</font> or if the patents are invalidated or     canceled, we may have to write off the related <font color="blue">intangible assets</font> and such an     event could <font color="blue">significant</font>ly reduce our earnings</td>
    </tr>
    <tr>
      <td>Any of our licenses, patents     or other <font color="blue">intellectual</font> property may be challenged, invalidated, canceled,     infringed or <font color="blue">circumvented</font> and may not provide any <font color="blue">competitive</font> advantage to     us</td>
    </tr>
    <tr>
      <td>If our <font color="blue">highly <font color="blue">qualified <font color="blue">management</font></font></font> and <font color="blue">technical personnel leave us</font>, our     business may suffer</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> our current <font color="blue">management</font>, particularly our founder and     Chief Executive Officer, Martine Rothblatt, Ph</td>
    </tr>
    <tr>
      <td>D, our <font color="blue">Executive Vice President </font>for     Business <font color="blue">Development </font>and Chief Financial Officer, Fred Hadeed, our Executive     Vice  President  for Strategic Planning, General Counsel and Corporate     Secretary, Paul Mahon, our <font color="blue">Executive Vice President </font>and Chief Operating     Officer  for  Production,  David  Walsh, our <font color="blue">Senior Vice President </font>for     Pharmaceutical Development, David Zaccardelli, Pharm</td>
    </tr>
    <tr>
      <td>D, and our Senior Vice     President for Biologics Production, <font color="blue">Development </font>and Supply, James Levin,     DVM While these <font color="blue">individuals</font> are <font color="blue">employed by us pursuant</font> to multi-year     employment <font color="blue"><font color="blue">agreement</font>s</font>, employment <font color="blue"><font color="blue">agreement</font>s</font> do not ensure the continued     retention of employees</td>
    </tr>
    <tr>
      <td>We do not maintain key person <font color="blue">life insurance on</font>     these officers</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will</font>       30     ______________________________________________________________________       depend in part on retaining the services of our <font color="blue">existing <font color="blue">management</font></font> and key     personnel and attracting and retaining <font color="blue">new highly qualified personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Expertise </font>in the field of cardiovascular medicine, infectious disease and     oncology is not <font color="blue">generally available</font> in the market, and <font color="blue">competition</font> for     <font color="blue">qualified <font color="blue">management</font></font> and personnel is intense</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">adequate insurance</font> and may have substantial exposure to     payment of <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>The testing, <font color="blue">manufacture</font>, marketing, and sale of <font color="blue">human drugs involve product</font>     <font color="blue">liability risks</font></td>
    </tr>
    <tr>
      <td>Although we currently have <font color="blue">product liability</font> insurance     covering claims up to dlra20 million per occurrence and in the aggregate for     our <font color="blue">pharmaceutical</font> products and <font color="blue">product liability</font> insurance covering claims     up to dlra10 million per occurrence and in the aggregate for our <font color="blue">telemedicine</font>     and  <font color="blue">arginine supplement products</font>, we may not be able to maintain this     <font color="blue">product liability</font> insurance at an acceptable cost, if at all</td>
    </tr>
    <tr>
      <td>In addition,     this <font color="blue">insurance may</font> not provide adequate coverage against potential losses</td>
    </tr>
    <tr>
      <td>If claims or <font color="blue">losses exceed</font> our liability <font color="blue">insurance coverage</font>, we <font color="blue">may go out</font>     of business</td>
    </tr>
    <tr>
      <td>We may not have, or may have to share rights to, <font color="blue">future <font color="blue">inventions</font></font> arising     from our license, <font color="blue">assignment</font> and alliance <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue">may lose potential</font>     profits or savings</td>
    </tr>
    <tr>
      <td><font color="blue">Pursuant  </font>to  our  <font color="blue"><font color="blue">agreement</font>s</font>  with certain business partners, any new     <font color="blue">inventions</font> or <font color="blue">intellectual</font> property that arise from our <font color="blue">activities</font> will be     owned jointly by us and these partners</td>
    </tr>
    <tr>
      <td>If we do not have rights to new     <font color="blue">development</font>s or <font color="blue">inventions</font> that arise during the terms of these <font color="blue"><font color="blue">agreement</font>s</font>,     or we have to share the <font color="blue">rights with others</font>, we may lose some or all of the     benefit of these new rights, which may mean a loss of <font color="blue">future profits</font> or     savings generated from improved <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we need <font color="blue">additional</font> financing and cannot obtain it, product <font color="blue">development</font>     and sales may be limited</td>
    </tr>
    <tr>
      <td>We may need to spend more <font color="blue">money than currently</font> expected because we may need     to change our product <font color="blue">development</font> plans or <font color="blue">product offerings</font> to address     <font color="blue">difficult</font>ies with <font color="blue">clinical studies</font>, to prepare for <font color="blue">commercial sales</font> or to     <font color="blue">continue sales</font> of Remodulin</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">additional</font> funds     on <font color="blue">commercially</font> reasonable terms or at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> funds are not     available, we may be compelled to delay <font color="blue">clinical studies</font>, curtail <font color="blue">operations</font>     or obtain <font color="blue">funds through collaborative arrangements</font> that may require us to     <font color="blue">relinquish rights</font> to <font color="blue">certain products</font> or <font color="blue">potential markets</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font> involve <font color="blue"><font color="blue">hazardous</font> materials</font>, and <font color="blue">improper handling</font> of these     <font color="blue">materials could expose us</font> to <font color="blue">significant</font> liabilities</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> and <font color="blue">manufacturing</font> <font color="blue">activities</font> involve the     <font color="blue">controlled use</font> of <font color="blue">chemicals</font> and <font color="blue"><font color="blue">hazardous</font> materials</font></td>
    </tr>
    <tr>
      <td>As a consequence, we     are subject to numerous federal, state, and local <font color="blue">environmental</font> and safety     laws and <font color="blue">regulations</font>, including those governing the <font color="blue">management</font>, storage and     disposal of <font color="blue"><font color="blue">hazardous</font> materials</font></td>
    </tr>
    <tr>
      <td>We may be required to incur <font color="blue">significant</font>     costs to <font color="blue">comply with</font> current or future <font color="blue">environmental</font> laws and <font color="blue">regulations</font>,     and substantial fines and penalties for failure to <font color="blue">comply with</font> these laws     and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>While we believe that we are currently in substantial     <font color="blue">compliance with</font> laws and <font color="blue">regulations</font> governing these materials, the risk of     <font color="blue"><font color="blue">accident</font>al</font>  <font color="blue">contamination</font>  or  injury  from  these <font color="blue">materials cannot</font> be     eliminated</td>
    </tr>
    <tr>
      <td>In the event of such an <font color="blue">accident</font>, we could be liable for civil     damages  that  result  or  for the cleanup of any release of <font color="blue">hazardous</font>     materials, the cost of <font color="blue">which could</font> be substantial</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such liability could</font>     exceed  our  resources and could have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price could</font> be volatile and <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s for securities of drug and bio<font color="blue">technology</font> companies are     <font color="blue">highly volatile</font>, and there are <font color="blue">significant</font> price and <font color="blue">volume fluctuations</font> in     the market that may be unrelated to <font color="blue">particular companies</font>’       31     ______________________________________________________________________       operating <font color="blue">performances</font></td>
    </tr>
    <tr>
      <td>The table below sets forth the high and low closing     prices for our <font color="blue">common stock</font> for the <font color="blue">periods indicated</font>:                                        High               Low               January 1, 2003 – <font color="blue">December </font>31, 2003                          $       24dtta65                          $       14dtta70                          January 1, 2004 – <font color="blue">December </font>31, 2004                          $       46dtta73                          $       20dtta51                          January 1, 2005 – <font color="blue">December </font>31, 2005                          $       77dtta82                          $       41dtta37           Our <font color="blue">stock price could</font> decline suddenly due to the <font color="blue">following factors</font>, among     others:       ·       <font color="blue">Quarterly </font>and annual financial and operating results;       ·       Failure to meet estimates or <font color="blue"><font color="blue">expectation</font>s</font> of securities analysts or     our <font color="blue">projections</font>;       ·       Public concern as to the safety of products developed by us or by     others;       ·        <font color="blue">Changes  </font>in  or  new  <font color="blue">legislation</font>  and  <font color="blue">regulations</font> <font color="blue">affecting</font>     <font color="blue">reimbursement</font> of <font color="blue">Remodulin </font>by Medicare or Medicaid;       ·       Announcements by us or others of <font color="blue">technological</font> innovations or new     products or <font color="blue">announcements</font> regarding our <font color="blue">existing products</font>;       ·       <font color="blue">Developments </font>in patent or other <font color="blue">proprietary</font> rights;       ·       Future sales of substantial amounts of <font color="blue">common stock</font> by us or our     <font color="blue">existing <font color="blue">stockholders</font></font>;       ·       The pace of <font color="blue">enrollment</font> in and the results of <font color="blue">clinical trial</font>s;       ·       Future sales of <font color="blue">common stock</font> by our <font color="blue">directors</font> and officers;       ·       Failure to maintain approvals to sell Remodulin;       ·       Timing and outcome of <font color="blue">additional</font> <font color="blue"><font color="blue">regulatory</font> approvals</font>; and       ·       General <font color="blue">market conditions</font></td>
    </tr>
    <tr>
      <td>Future sales of shares of our <font color="blue">common stock</font> may depress our stock price</td>
    </tr>
    <tr>
      <td>If we issue <font color="blue">common stock</font> to <font color="blue">raise capital</font>, or our <font color="blue"><font color="blue">stockholders</font> transfer</font>     their ownership of our <font color="blue">common stock</font> or sell a substantial number of shares     of <font color="blue">common stock</font> in the <font color="blue">public market</font>, or <font color="blue">investors become concerned</font> that     substantial <font color="blue">sales might</font> occur, the <font color="blue">market price</font> of our <font color="blue">common stock</font> could     decrease</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2005, we filed a <font color="blue">shelf registration statement covering</font>     the <font color="blue">potential sale</font> of up to <font color="blue">five million shares</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In     addition, each of our <font color="blue">four <font color="blue">executive officers</font></font> has announced their adoption     of 10b5-1 prearranged trading plans</td>
    </tr>
    <tr>
      <td>In <font color="blue">accordance with</font> these plans, twice     <font color="blue">each month</font> these <font color="blue"><font color="blue">executives</font> sell</font> a specified number of our <font color="blue">common stock</font>     either owned by them or acquired through the exercise of <font color="blue">stock options</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">executives</font> and our <font color="blue">directors</font> may choose to sell <font color="blue">additional</font>     <font color="blue">shares outside</font> of 10b5-1 trading plans and <font color="blue">one executive</font> and five <font color="blue">directors</font>     have done so</td>
    </tr>
    <tr>
      <td>In addition, Toray Industries, Inc</td>
    </tr>
    <tr>
      <td>has an option to acquire     500cmam000 shares of our <font color="blue">common stock</font> and <font color="blue">piggyback registration rights with</font>     respect  to  such  shares  that  arise if and when this <font color="blue">option becomes</font>     exercisable</td>
    </tr>
    <tr>
      <td>A decrease in our <font color="blue">common stock</font> price could make it <font color="blue">difficult</font>     for us to <font color="blue">raise capital</font> by selling stock or to pay for <font color="blue"><font color="blue">acquisition</font>s</font> using     stock</td>
    </tr>
    <tr>
      <td>To the extent outstanding options are exercised or <font color="blue">additional</font> shares     of <font color="blue">capital stock</font> are issued, <font color="blue">existing <font color="blue">stockholders</font></font> may incur <font color="blue">additional</font>     dilution</td>
    </tr>
    <tr>
      <td>32     ______________________________________________________________________       <font color="blue">Provisions of <font color="blue">Delaware </font></font>law and our <font color="blue">certificate</font> of <font color="blue">incorporation</font>, by-laws and     <font color="blue">shareholder rights</font> plan could prevent or delay a change of control or change     in <font color="blue">management</font> that could be <font color="blue">beneficial</font> to us and our public <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Certain provisions of <font color="blue">Delaware </font>law and our <font color="blue">certificate</font> of <font color="blue">incorporation</font>,     by-laws and <font color="blue">shareholder rights</font> plan may prevent, delay or discourage:       ·       A merger, tender offer or <font color="blue">proxy contest</font>;       ·        The <font color="blue">assumption</font> of <font color="blue">control by</font> a holder of a large block of our     securities; and       ·        The  <font color="blue">replacement</font>  or  removal  of  current  <font color="blue">management</font> by our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>For example, our <font color="blue">certificate</font> of <font color="blue">incorporation</font> divides the board of <font color="blue">directors</font>     into three classes, with members of each class to be elected for staggered     three-year terms</td>
    </tr>
    <tr>
      <td>This <font color="blue">provision may</font> make it more <font color="blue">difficult</font> for <font color="blue">stockholders</font>     to change the majority of <font color="blue">directors</font> and <font color="blue">may hinder accumulations</font> of large     blocks of <font color="blue">common stock</font> by limiting the <font color="blue">voting power</font> of such blocks</td>
    </tr>
    <tr>
      <td>This may     further result in <font color="blue">discouraging</font> a change of control or change in current     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Our existing <font color="blue">directors</font> and <font color="blue">executive officers</font> own a substantial block of our     stock  and might be able to influence the outcome of matters requiring     <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">directors</font> and named <font color="blue">executive officers</font> <font color="blue">beneficial</font>ly owned <font color="blue">approximately</font>     10dtta1  percent of our outstanding <font color="blue">common stock</font> as of <font color="blue">December </font>31, 2005,     including <font color="blue">stock options</font> that could be <font color="blue">exercised by</font> those <font color="blue">directors</font> and     executive  officers  within  60 days  of that date</td>
    </tr>
    <tr>
      <td>Accordingly, these     <font color="blue">stockholders</font> as a group might be able to influence the outcome of matters     requiring  <font color="blue">approval by</font> our <font color="blue">stockholders</font>, including the election of our     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">stockholder influence could delay</font> or prevent a change of     <font color="blue">control with respect</font> to us</td>
    </tr>
    <tr>
      <td>If <font color="blue">stockholders</font> do not receive dividends, <font color="blue">stockholders</font> must rely on stock     <font color="blue">appreciation</font> for any return on their <font color="blue">investment</font> in us</td>
    </tr>
    <tr>
      <td>We have never declared or <font color="blue">paid cash dividends on</font> any of our <font color="blue">capital stock</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently intend</font> to retain our earnings for future growth and therefore     do not anticipate <font color="blue">paying cash dividends</font> in the future</td>
    </tr>
  </tbody>
</table>